Pfizer is forecasting about 15-billion dollars in revenue from COVID-19 vaccines in 2021. The drugmaker said in its quarterly earnings report overall revenue this year will likely be around 60-billion.
Pfizer topped analysts’ fourth quarter revenue projections. Despite the good numbers, shares of the company are in the red in early trading.
